Sweden
· Delayed Price · Currency is SEK Moberg Pharma AB Statistics
Total Valuation
Moberg Pharma AB has a market cap or net worth of SEK 1.50 billion. The enterprise value is 1.18 billion.
| Market Cap | 1.50B |
| Enterprise Value | 1.18B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Moberg Pharma AB has 46.69 million shares outstanding.
| Shares Outstanding | 46.69M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.44% |
| Owned by Institutions (%) | 43.58% |
| Float | 41.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 165.80 |
| PB Ratio | 1.58 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -51.72 |
| EV / Sales | 238.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.49, with a Debt / Equity ratio of 0.43.
| Current Ratio | 12.49 |
| Quick Ratio | 12.32 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -124.87 |
Financial Efficiency
Return on equity (ROE) is -3.13% and return on invested capital (ROIC) is -2.51%.
| Return on Equity (ROE) | -3.13% |
| Return on Assets (ROA) | -2.43% |
| Return on Capital (ROIC) | -2.51% |
| Revenue Per Employee | 547,667 |
| Profits Per Employee | -2.53M |
| Employee Count | 9 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +382.71% in the last 52 weeks. The beta is 0.97, so Moberg Pharma AB's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | +382.71% |
| 50-Day Moving Average | 33.72 |
| 200-Day Moving Average | 23.93 |
| Relative Strength Index (RSI) | 46.56 |
| Average Volume (20 Days) | 288,865 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Moberg Pharma AB had revenue of SEK 4.93 million and -22.75 million in losses. Loss per share was -0.89.
| Revenue | 4.93M |
| Gross Profit | 3.21M |
| Operating Income | -29.34M |
| Pretax Income | -27.33M |
| Net Income | -22.75M |
| EBITDA | -28.51M |
| EBIT | -29.34M |
| Loss Per Share | -0.89 |
Balance Sheet
The company has 325.96 million in cash and 3.99 million in debt, giving a net cash position of 321.97 million or 6.90 per share.
| Cash & Cash Equivalents | 325.96M |
| Total Debt | 3.99M |
| Net Cash | 321.97M |
| Net Cash Per Share | 6.90 |
| Equity (Book Value) | 929.00M |
| Book Value Per Share | 20.27 |
| Working Capital | 320.02M |
Cash Flow
| Operating Cash Flow | -41.21M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 65.19% |
| Operating Margin | -595.33% |
| Pretax Margin | -554.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Moberg Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -2.78% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on May 24, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | May 24, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |